Suresh, S.; Huard, S.; Brisson, A.; Némati, F.; Dakroub, R.; Poulard, C.; Ye, M.; Martel, E.; Reyes, C.; Silvestre, D.C.;
et al. PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer. Cancers 2022, 14, 306.
https://doi.org/10.3390/cancers14020306
AMA Style
Suresh S, Huard S, Brisson A, Némati F, Dakroub R, Poulard C, Ye M, Martel E, Reyes C, Silvestre DC,
et al. PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer. Cancers. 2022; 14(2):306.
https://doi.org/10.3390/cancers14020306
Chicago/Turabian Style
Suresh, Samyuktha, Solène Huard, Amélie Brisson, Fariba Némati, Rayan Dakroub, Coralie Poulard, Mengliang Ye, Elise Martel, Cécile Reyes, David C. Silvestre,
and et al. 2022. "PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer" Cancers 14, no. 2: 306.
https://doi.org/10.3390/cancers14020306
APA Style
Suresh, S., Huard, S., Brisson, A., Némati, F., Dakroub, R., Poulard, C., Ye, M., Martel, E., Reyes, C., Silvestre, D. C., Meseure, D., Nicolas, A., Gentien, D., Fayyad-Kazan, H., Le Romancer, M., Decaudin, D., Roman-Roman, S., & Dubois, T.
(2022). PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer. Cancers, 14(2), 306.
https://doi.org/10.3390/cancers14020306
